D-Minus Hemolytic Uremic Syndrome
Symptoms, Doctors, Treatments, Advances & More

D-Minus Hemolytic Uremic Syndrome Overview

Save information for later
Sign Up

Learn About D-Minus Hemolytic Uremic Syndrome

What is the definition of D-Minus Hemolytic Uremic Syndrome?
D-minus (diarrhea negative) hemolytic uremic syndrome is an extremely rare, progressive genetic disease characterized by low levels of red blood cells (hemolytic anemia), low platelets (thrombocytopenia), and an inability of the kidneys to process waste products from the blood (uremia).
What are the symptoms of D-Minus Hemolytic Uremic Syndrome?
Symptoms of D-minus hemolytic uremic syndrome may include malaise, fatigue, irritability, lethargy, decreased urine, paleness, scattered bruising, gastrointestinal bleeding, high blood pressure, headaches, double vision, facial paralysis, stroke, seizures, coma, fluid in the lungs, enlarged heart, and kidney failure.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for D-Minus Hemolytic Uremic Syndrome?
Treatment for D-minus hemolytic uremic syndrome may include intravenous nutrition and fluid replacement, kidney or peritoneal dialysis, blood transfusion, vasodilators, medications, such as eculizumab and ultomiris (favulizumab-cwyz), plasma exchange (plasmapheresis), immunosuppressive therapy, or kidney transplant.
Who are the top D-Minus Hemolytic Uremic Syndrome Local Doctors?
Elite in D-Minus Hemolytic Uremic Syndrome
Dr. Robert A. Brodsky
Hematology | Oncology
Elite in D-Minus Hemolytic Uremic Syndrome
Dr. Robert A. Brodsky
Hematology | Oncology
Referral may be required

Sidney Kimmel Comprehensive Cancer Center

401 North Broadway Street, Weinberg BLDG, Weinberg BLDG, 
Baltimore, MD 
410-955-8964
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Brodsky is a Hematologist and an Oncologist practicing medicine in Baltimore, Maryland. Dr. Brodsky is rated as an Elite provider by MediFind in the treatment of D-Minus Hemolytic Uremic Syndrome. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy. Dr. Brodsky is board certified in American Board Of Internal Medicine. Dr. Brodsky is currently accepting new patients.

Elite in D-Minus Hemolytic Uremic Syndrome
Elite in D-Minus Hemolytic Uremic Syndrome
Referral may be required
Milan, IT 

Gianluigi Ardissino practices practicing medicine in Milan, Italy. Mr. Ardissino is rated as an Elite expert by MediFind in the treatment of D-Minus Hemolytic Uremic Syndrome. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Hemolytic-Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Atypical Hemolytic Uremic Syndrome (aHUS), and Kidney Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in D-Minus Hemolytic Uremic Syndrome
Elite in D-Minus Hemolytic Uremic Syndrome
Referral may be required
555 University Avenue, M5G 1X8, 
Toronto, ON, CA 

Christoph Licht practices practicing medicine in Toronto, Canada. Mr. Licht is rated as an Elite expert by MediFind in the treatment of D-Minus Hemolytic Uremic Syndrome. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Hemolytic-Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Atypical Hemolytic Uremic Syndrome (aHUS), and Kidney Transplant.

View All Doctors
What are the latest D-Minus Hemolytic Uremic Syndrome Clinical Trials?
A Non-interventional Study Evaluating Ravulizumab Treatment Outcomes in Polish Patients With Atypical Hemolytic Uremic Syndrome
A Non-interventional Study Evaluating Ravulizumab Treatment Outcomes in Polish Patients With Atypical Hemolytic Uremic Syndrome
Enrollment Status: Recruiting
Publish Date: August 18, 2026
Intervention Type: Drug

Summary: This multicenter, observational cohort study uses retrospective collection of past medical history and prospective follow-up to capture longitudinal data on the management and clinical outcomes of patients with atypical hemolytic uremic syndrome (aHUS) treated with ravulizumab as part of routine clinical practice under Poland's National Drug Program (NDP).

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multi-center, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Iptacopan in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Who Have Completed a Preceding Iptacopan Phase 3 Study in aHUS
A Multi-center, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Iptacopan in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Who Have Completed a Preceding Iptacopan Phase 3 Study in aHUS
Enrollment Status: Recruiting
Publish Date: June 04, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: This is a multicenter, single arm, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with aHUS.

View All Clinical Trials